This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
AI Decision Support System Aims to Improve Battlefield Triage
APPRAISE helps combat medics identify hemorrhage risk earlier and make faster triage and evacuation decisions.
7m watch -
VA Deputy Secretary on Resuming EHR Rollout
VA resumed rollout of its EHRM program this weekend after a three-year pause, and Paul Lawrence discusses early feedback and lessons learned.
15m watch -
Former GSA, NASA Leader on Federal Acquisition Leadership
Former GSA and NASA executive Mary Davie shares advice for public servants considering a move to the private sector.
6m watch -
Inside the Army’s FUZE Model for Rapid Tech Deployment
FUZE Director Matthew Willis explains how the Army is using a venture-style investment model to move emerging technologies from prototype to the field faster.
10m listen